Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Six-month open-label outpatient trial of inhaled insulin (Exubera) vs subcutaneous human insulin in poorly controlled type 2 diabetes on two oral agents
2005-003504-11Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2005
- Countries
- 1
01
Overview
Phase 3, open-label trial of Technosphere insulin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Pfizer. Primary endpoint: Primary glycemic control endpoints. Started Dec 2005; status: completed.
02
Drugs
Technosphere insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-003504-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003504-11.